Comprehensive Business & Financial Analysis — From Suven Pharmaceuticals to India's Technology-Led Global CDMO
From Suven Pharmaceuticals to Cohance — A technology-led integrated CDMO transformation
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals) is an integrated, technology-led global CDMO headquartered in Hyderabad. Demerged from Suven Life Sciences in 2020, it was acquired by Advent International in 2023 and merged with Cohance Lifesciences (effective Jan 1, 2025). Strategic acquisitions of Sapala Organics (oligonucleotides), NJ Bio (ADC CRDMO), and Casper Pharma (formulations) have created a unified platform across three pillars: Pharma CDMO, Specialty Chemicals, and API+. Vision: US$1 billion revenue by 2030 with mid-30s% EBITDA margins.
Critical financial metrics evolution from FY22 through 9M FY26 — WCC, margins, FCF, capex, D&A, debt
FY22-FY24 are Suven standalone. FY25 onward is the merged Cohance consolidated entity. Numbers in ₹ Crore.
| Metric | FY22 | FY23 | FY24 | FY25 (Cons.) | 9M FY26 (Cons.) |
|---|---|---|---|---|---|
| Revenue from Operations | 1,320 | 1,330 | 1,051 | 2,609 | 1,650 |
| Cost of Materials | 459 | 421 | 330 | 815 | 449 |
| Gross Profit | 861 | 909 | 721 | 1,794 | 1,201 |
| Gross Margin % | 65.2% | 68.3% | 68.6% | 68.7% | 72.8% |
| Employee Cost | 100 | 100 | 125 | 410 | 345 |
| Other Expenses | 133 | 181 | 188 | 530 | 410 |
| EBITDA | 628 | 628 | 408 | 854 | 348 |
| EBITDA Margin % | 47.6% | 47.2% | 38.8% | 32.7% | 21.1% |
| Depreciation & Amortization | 39 | 43 | 52 | 148 | 136 |
| D&A as % of Revenue | 3.0% | 3.2% | 4.9% | 5.7% | 8.2% |
| Finance Costs | 6 | 5 | 8 | 42 | 38 |
| Profit Before Tax | 583 | 580 | 348 | 664 | 174 |
| Tax | 164 | 147 | 52 | 177 | 23 |
| Profit After Tax | 419 | 433 | 296 | 487 | 151 |
| Net Margin % | 31.7% | 32.6% | 28.2% | 18.7% | 9.2% |
| Metric | FY22 | FY23 | FY24 | FY25 (Cons.) | 9M FY26 (Cons.) |
|---|---|---|---|---|---|
| Total Assets | 1,805 | 1,958 | 2,180 | 5,540 | 5,750 |
| Net Fixed Assets (PPE + CWIP) | 560 | 695 | 820 | 2,450 | 3,529 |
| Goodwill + Intangibles | 2 | 2 | 3 | 1,180 | 1,350 |
| Inventories | 283 | 311 | 380 | 552 | 599 |
| Trade Receivables | 481 | 234 | 270 | 594 | 586 |
| Cash & Equivalents | 30 | 43 | 50 | 390 | 432 |
| Investments (MF/FD) | 481 | 309 | 714 | 290 | 303 |
| Shareholders' Equity | 1,521 | 1,749 | 1,950 | 3,548 | 3,820 |
| Total Debt | 96 | 70 | 45 | 196 | 256 |
| Net Debt (Debt - Cash - Investments) | (415) | (282) | (719) | (484) | (479) |
| Debt / Equity | 0.06 | 0.04 | 0.02 | 0.06 | 0.07 |
| Trade Payables | 106 | 60 | 75 | 350 | 351 |
NWC days reflect the cash conversion cycle — inventory + receivable days minus payable days.
| Component | FY22 | FY23 | FY24 | FY25 | 9M FY26 |
|---|---|---|---|---|---|
| Inventory Days | 79 | 86 | 110 | 77 | 98 |
| Receivable Days | 66 | 30 | 42 | 83 | 97 |
| Payable Days | 29 | 16 | 26 | 49 | 58 |
| Net Working Capital Cycle | 116 | 100 | 126 | 111 | 128 |
| ₹ Crore | FY22 | FY23 | FY24 | FY25 (Cons.) | 9M FY26 (Cons.) |
|---|---|---|---|---|---|
| Operating Cash Flow | 270 | 484 | 360 | 876 | 322 |
| Capital Expenditure | 75 | 145 | 200 | 310 | 161 |
| Free Cash Flow (OCF - Capex) | 195 | 339 | 160 | 566 | 161 |
| FCF Margin % | 14.8% | 25.5% | 15.2% | 21.7% | 9.8% |
| Capex as % of Revenue | 5.7% | 10.9% | 19.0% | 11.9% | 9.8% |
D&A has risen sharply post-merger and acquisitions — from ₹39 Cr in FY22 to a run-rate of ₹180+ Cr annualized in FY26. This reflects the asset-heavy CDMO platform being built.
| ₹ Crore | FY22 | FY23 | FY24 | FY25 | 9M FY26 |
|---|---|---|---|---|---|
| Depreciation & Amortization | 39 | 43 | 52 | 148 | 136 |
| D&A as % of Revenue | 3.0% | 3.2% | 4.9% | 5.7% | 8.2% |
| D&A as % of Fixed Assets | 7.0% | 6.2% | 6.3% | 6.0% | 5.1% |
| EBITDA - D&A gap widening | 589 | 585 | 356 | 706 | 212 |
The 141% YoY increase in D&A in Q1FY26 vs Q1FY25 is primarily driven by the consolidation of NJ Bio and Sapala Organics assets. As these platforms scale revenue, the D&A burden as % of sales is expected to normalize to 5-6%.
| Ratio | FY22 | FY23 | FY24 | FY25 | 9M FY26 (Ann.) |
|---|---|---|---|---|---|
| Return on Equity (%) | 27.5% | 24.8% | 15.2% | 13.7% | ~11.2% |
| Return on Capital Employed (%) | 38.3% | 33.1% | 17.6% | 12.6% | ~16.1% |
| Net Debt / EBITDA | Net Cash | Net Cash | Net Cash | Net Cash | 0.29x |
| Current Ratio | 5.31 | 6.19 | 3.32 | 10.45 | ~2.87 |
| Debt / Equity | 0.06 | 0.04 | 0.02 | 0.06 | 0.07 |
| Interest Coverage (EBITDA/Interest) | 105x | 126x | 51x | 20x | ~9x |
ROCE declined from 38% to ~16% primarily due to the massive equity and asset base expansion from Cohance merger and NJ Bio/Sapala acquisitions adding ₹1,350 Cr+ in goodwill and intangibles. As acquired platforms scale, ROCE is expected to recover toward 25%+ by FY28.
What Cohance acquired, capabilities gained, and the impact on consolidated financials
Capabilities acquired: End-to-end ADC CRDMO leadership. Payload-linker synthesis, bioconjugation, ADC analytical platform. 150+ clients, 500+ projects completed, 140+ employees including 100+ scientists.
Strategic value: Proprietary Camptothecin payload technology, exclusive payload intermediate supplier to major innovator. ~40% of clinical ADC candidates use Camptothecin-based payloads. $10M expansion underway for Phase 2B capability by FY27.
Financial impact: First-year consolidation creating margin drag. NJ Bio is in investment phase — revenue is early-stage but growing. Biotech funding winter impacting near-term customer spending. Added ~₹600+ Cr in goodwill to consolidated balance sheet.
Capabilities acquired: World's only commercial-scale Ribo DNA (ICNA) manufacturing. Oligonucleotide building block synthesis, GalNAc synthesis (>15 synthetic steps backward integration), modified amidites, conformationally constrained nucleic acids.
Strategic value: Positions Cohance in the US$18.4 billion oligonucleotide market (21.8% CAGR). First GMP orders from customers scheduled Oct-Nov 2026. Working on 35+ active molecules across building blocks.
Financial impact: Early revenue stage; ₹230 Mn invested in cGMP facility at Nacharam. Upgraded analytical infrastructure with supercritical fluid chromatography and high-resolution mass spectroscopy.
Capabilities acquired: API+ business (merchant APIs, backward integration), ADC platform with commercial products, specialty chemicals CDMO, 5+ FDA-audited facilities, formulation business. Combined capacity ~2,650 KL.
Strategic value: Created diversified end-to-end CDMO. Cohance had 16% revenue CAGR and 27% EBITDA CAGR over 4 years. 10% incremental EBITDA synergy expected over 4 years.
Financial impact: Revenue more than doubled (~₹1,050 Cr → ~₹2,600 Cr). But Cohance's API+ segment operates at lower margins (EBITDA ~20%) vs Suven's CDMO (40%+), causing blended margin dilution to 32-34%.
Capabilities acquired: FDA-approved formulation facility with 1.2 billion unit capacity. 22+ ANDAs approved with multiple pending. Entry into US generic formulation market.
Financial impact: Casper was loss-making initially. Merged into Suven Pharmaceuticals in May 2025. Nacharam unit received OAI/warning letter from US-FDA — contributes <2% of revenue.
Yes, meaningfully. The Cohance merger and subsequent acquisitions have caused significant near-term dilution across key financial metrics:
| Metric | FY24 (Pre-Merger Suven) | FY25 (Consolidated) | 9M FY26 (Consolidated) | Impact |
|---|---|---|---|---|
| EBITDA Margin | 38.8% | 32.7% | 21.1% | ▼ Cohance's API+ at ~20% margin + NJ Bio investment phase |
| Net Margin | 28.2% | 18.7% | 9.2% | ▼ Higher D&A, finance costs, lower-margin segments |
| ROCE | 17.6% | 12.6% | ~16.1% | ▼ ₹1,350 Cr goodwill/intangibles inflated capital employed |
| D&A / Revenue | 4.9% | 5.7% | 8.2% | ▼ NJ Bio & Sapala assets adding depreciation burden |
| Goodwill + Intangibles | ₹3 Cr | ₹1,180 Cr | ₹1,350 Cr | ▲ Massive increase from Cohance, NJ Bio, Sapala |
| Employee Cost / Revenue | 11.9% | 15.7% | 20.9% | ▲ NJ Bio's 140+ employees (100+ scientists) in high-cost US |
However, management views this as "investment ahead of scale". The acquired platforms (ADC, oligonucleotides) are in early commercialization with high growth potential. As these scale — particularly NJ Bio's ADC platform and Sapala's oligo capabilities — margins are expected to recover to mid-30s% EBITDA by FY28-30. The ₹1,350 Cr in goodwill/intangibles represents future earnings potential that hasn't yet materialized in revenue.
Expertise, facility capacity, locations, and growth prospects
Core strength spanning 30+ years of complex chemistry expertise.
Rapidly growing ADCs, oligonucleotides, bioconjugation platforms.
Primary Pharma CDMO hub. 93 reactors (500L–10KL). ~300+ KL. New block commissioned FY24 (₹200 Cr).
APIs, Intermediates, CMO. 307 KL. 45 reactors (3KL–12KL). Specialty & AgChem.
API & Formulation. 120 KL. cGMP Oligo suites under construction. US-FDA audited.
R&D Pilot Plant. 32 reactors. Discovery, Analytical, Kilo Lab.
25,000+ sq ft R&D. Advanced drug development. Operational since Jun 2024.
API manufacturing. EU & US-FDA cleared (zero observations).
Specialty Chemicals, AgChem, Performance Chemicals. Green steam.
ADC CRDMO. 140+ employees, 100+ scientists. $10M expansion for Phase 2B by FY27.
| Modality | Global Market | CAGR | Cohance Position |
|---|---|---|---|
| Small Molecule CDMO | US$146B (2023) | 7.3% | 30+ yrs expertise, 16 commercial molecules, 900+ projects delivered |
| ADC | US$1.5B (2025) | ~25% | NJ Bio — 150+ clients, exclusive payload supplier, 40% clinical candidates |
| Oligonucleotides | US$18.4B (2034) | 21.8% | Sapala — world's only commercial Ribo DNA (ICNA); first GMP orders Oct-Nov 2026 |
| Specialty Chemicals | US$641B (2023) | 5.2% | Dedicated SBU — AgChem, OLED, Photochromic, Semiconductor chemicals |
Quarter-wise vertical bar charts with timeline on X-axis for each business segment
Evolution across four transformational phases
COVID Molecule Fadeout: ~₹120 Cr revenue in FY22 created distorted base.
Global AgChem Destocking: Crushed Specialty Chemicals from FY23–FY25.
Raw Material Inflation: Solvents, logistics costs surged in FY22-23.
Management Transition: Promoter → professional team; restructuring costs.
Lumpy CDMO Nature: 6-month visibility; quarter-to-quarter variability.
Destocking in 2 Large Molecules: ~₹260 Cr revenue impact from customer inventory normalization.
NJ Bio Consolidation Drag: High-cost US base; biotech funding winter; margin compression.
Nacharam OAI/Warning Letter: US-FDA formulation site; <2% revenue impact; remediation underway.
Patent Expiry: One large commercial molecule facing patent cliff — lower reload volumes.
Margin Compression: EBITDA from 34% (FY25) to ~21% (9M FY26) due to integration + investment phase.
Target implies ~25-30% revenue CAGR from FY26 base. Three growth engines: Pharma CDMO, Specialty Chemicals, API+. Mid-30s% EBITDA margins. ROCE recovery to 25%+.
Q3FY26 at top. Scroll down — each quarter appears as you scroll.
Cohance Lifesciences Comprehensive Analysis • 26 Concalls + 3 Annual Reports + 3 Quarterly Results • FY21–FY26
For informational purposes only. Not investment advice.